CA2556032A1 - Modification chimique specifique de site de peptides derives de gp41 du vih - Google Patents

Modification chimique specifique de site de peptides derives de gp41 du vih Download PDF

Info

Publication number
CA2556032A1
CA2556032A1 CA002556032A CA2556032A CA2556032A1 CA 2556032 A1 CA2556032 A1 CA 2556032A1 CA 002556032 A CA002556032 A CA 002556032A CA 2556032 A CA2556032 A CA 2556032A CA 2556032 A1 CA2556032 A1 CA 2556032A1
Authority
CA
Canada
Prior art keywords
hiv
amine
amino acid
peptide
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002556032A
Other languages
English (en)
Inventor
Brian Bray
Huyi Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trimeris Inc
Original Assignee
Trimeris, Inc.
Brian Bray
Huyi Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trimeris, Inc., Brian Bray, Huyi Zhang filed Critical Trimeris, Inc.
Publication of CA2556032A1 publication Critical patent/CA2556032A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002556032A 2004-03-15 2005-03-08 Modification chimique specifique de site de peptides derives de gp41 du vih Abandoned CA2556032A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55306304P 2004-03-15 2004-03-15
US60/553,063 2004-03-15
PCT/US2005/007486 WO2005089796A1 (fr) 2004-03-15 2005-03-08 Modification chimique specifique de site de peptides derives de gp41 du vih

Publications (1)

Publication Number Publication Date
CA2556032A1 true CA2556032A1 (fr) 2005-09-29

Family

ID=34993445

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002556032A Abandoned CA2556032A1 (fr) 2004-03-15 2005-03-08 Modification chimique specifique de site de peptides derives de gp41 du vih

Country Status (6)

Country Link
EP (1) EP1734994A1 (fr)
JP (1) JP2007529522A (fr)
CN (1) CN1929860A (fr)
CA (1) CA2556032A1 (fr)
IL (1) IL177268A0 (fr)
WO (1) WO2005089796A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4805911B2 (ja) 2004-03-15 2011-11-02 ネクター セラピューティクス Ｈｉｖ侵入阻害剤のポリマー系組成物及び複合体
EP1954302A4 (fr) * 2005-11-02 2009-11-04 Ambrx Inc Inhibiteurs de fusions polypeptidiques biosynthetiques
CN1793170A (zh) * 2005-12-14 2006-06-28 中国人民解放军军事医学科学院生物工程研究所 抑制hiv病毒融合的多肽及其用途
CA2651793C (fr) * 2006-02-02 2015-07-07 Trimeris, Inc. Peptides inhibiteurs de fusion du vih a proprietes biologiques ameliorees
KR20100016142A (ko) * 2007-04-03 2010-02-12 트라이머리스, 인코퍼레이티드 항바이러스 펩티드 치료제 전달용 신규 제제
WO2011095989A2 (fr) * 2010-02-04 2011-08-11 Matrix Laboratories Ltd Procédé amélioré pour préparer de l'enfuvirtide
EP2550290B1 (fr) * 2010-03-24 2015-12-02 Medical Research Council Méthode de modifier une lysine spécifique
CN102883734B (zh) * 2010-05-21 2018-01-02 Xl-蛋白有限责任公司 生物合成的脯氨酸/丙氨酸无规卷曲多肽及其用途
CN104788548B (zh) * 2014-01-20 2018-06-05 中国人民解放军军事医学科学院毒物药物研究所 新型抗hiv感染多肽及其利用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6271198B1 (en) * 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same

Also Published As

Publication number Publication date
CN1929860A (zh) 2007-03-14
JP2007529522A (ja) 2007-10-25
IL177268A0 (en) 2006-12-10
WO2005089796A1 (fr) 2005-09-29
EP1734994A1 (fr) 2006-12-27

Similar Documents

Publication Publication Date Title
EP1989220B1 (fr) Peptides inhibiteurs de fusion du vih à propriétés biologiques améliorées
CA2556032A1 (fr) Modification chimique specifique de site de peptides derives de gp41 du vih
WO2001003723A1 (fr) Polypeptides hybrides possedant des proprietes pharmacocinetiques ameliorees
US20100016225A1 (en) CONJUGATES COMPRISED OF POLYMER AND HIV gp-41-DERIVED PEPTIDES AND THEIR USE IN THERAPY
CN114736272B (zh) 一种优化病毒膜融合抑制剂的方法及广谱抗冠状病毒脂肽和应用
WO2008124013A1 (fr) Nouvelles formulations destinées à l'application de thérapies peptidiques antivirales
CN108727475B (zh) 强效抑制hiv的脂肽、其衍生物、其药物组合物及其用途
WO2006105201A2 (fr) Conjugues constitues d'acide gras et de peptide derive du gp41 du vih
WO2021223422A1 (fr) Polypeptide anti-vih modifié avec un peg à poids moléculaire élevé, sa préparation et son utilisation
AU2017410525A1 (en) Potent HIV inhibiting lipopeptide, derivative thereof, pharmaceutical composition thereof and use thereof
US20100261876A1 (en) Novel methods of synthesis for therapeutic antiviral peptides
CN100455594C (zh) 抑制hiv病毒融合的多肽及其用途
AU2003270894B2 (en) Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
BRAY et al. Patent 2556032 Summary
MXPA06009352A (es) Modificacion quimica especifica del sitio de peptidos derivados de gp 41 del vih
US20140357577A1 (en) HIV Membrane Fusion Inhibitors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued